Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Halix Completes New cGMP Facility | Contract Pharma

What are you searching for?

Sign in
Breaking News

Halix Completes New cGMP Facility

Company meets aggressive timelines for new biomanufacturing facility

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Halix, a contract development and manufacturing organization (CDMO) of clinical and commercial proteins and viral products, based in the Netherlands, said they have met their major milestone with the interim delivery of their new 6,700 square meter cGMP facility in Leiden Bio Science Park.
 
Following one year of construction, Halix has completed its new state-of-the-art cGMP facility for the development and production of biopharmaceutical drug substances.
 
The new five-level production facility contains a state-of-the-art manufacturing line for viral vaccines and viral vectors and a separate protein manufacturing area with a capacity up to 1,000 liter single-use bioreactors. In addition, lab space is available for process development, analytical development and quality control. All cleanroom areas have a unidirectional process flow and are designed to allow commercial manufacturing of biopharmaceuticals products.
 
“This new facility offers our current and future clients capacity and flexibility for future expansion and will allow for cGMP manufacturing solutions for viral products, proteins, gene therapy and client-specific new technologies,” said Roland Hecht, chief customer officer, Halix.
 
Alex Huybens, chief operations officer, said, “We are very pleased to have met this major milestone for our new manufacturing facility. We have made great progress under very aggressive timelines. After a construction time of just 12 months we are now able to start production of viral products and protein production will follow soon. This milestone aligns with our growth and expansion strategy that will enable us to accommodate the growing market demand as well as our clients’ demands.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics